http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110354095-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db9efde660b78f98b102046e09d07ab7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbf1a4416f901ab2812eb22d79641108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ee668806e7d7c5c8fab6fd49b4b5dfe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52babe1ef25758d140b689980a0b6217 |
| publicationDate | 2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110354095-A |
| titleOfInvention | pH-sensitive hyaluronic acid nano drug-loaded particles targeting atherosclerosis and preparation method thereof |
| abstract | The invention discloses a preparation method of pH-sensitive hyaluronic acid nano drug-loaded particles targeting atherosclerosis, belonging to the technical field of new drug preparations, comprising: 1) a linker with a terminal hydrazine group is covalently bonded to hyaluronic acid acid to obtain hyaluronic acid derivatives; 2) graft the aldehyde compound containing hydrophobic chains to hyaluronic acid derivatives through the terminal hydrazine group to obtain pH-sensitive hyaluronic acid copolymers containing hydrazone bonds; Atherosclerotic drug encapsulation into a hydrophobic core of a pH-sensitive hyaluronic acid copolymer. The invention also discloses the medicine particles thereof. The present invention uses biodegradable and biocompatible materials, which are metabolized and excreted through normal physiological pathways; the carrier has multi-targeting properties, and hyaluronic acid passes CD44 and Stabilin overexpressed on the surface of atherosclerotic plaque cells. The 2 receptors are specifically combined to release drugs in response to the acidic inflammatory environment, achieving the combined treatment of antioxidant drugs and anti-atherosclerotic drugs. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114478829-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114478829-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113041365-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102354429-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210096931-A |
| priorityDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.